| 16.8 -0.25 (-1.47%) | 01-30 15:48 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.33  |
1-year : | 21.8 |
| Resists | First : | 17.4 |
Second : | 18.67 |
| Pivot price | 16.93 |
|||
| Supports | First : | 15.36 |
Second : | 12.78 |
| MAs | MA(5) : | 16.92 |
MA(20) : | 16.99 |
| MA(100) : | 12.85  |
MA(250) : | 9.75 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 44.2 |
D(3) : | 47.2 |
| RSI | RSI(14): 50.4 |
|||
| 52-week | High : | 18.67 | Low : | 3.97 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ FTRE ] has closed above bottom band by 37.9%. Bollinger Bands are 22.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.18 - 17.26 | 17.26 - 17.34 |
| Low: | 15.88 - 15.97 | 15.97 - 16.06 |
| Close: | 16.9 - 17.04 | 17.04 - 17.18 |
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
Thu, 29 Jan 2026
Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call - Yahoo Finance Singapore
Sat, 24 Jan 2026
Fortrea Holdings Inc. (NASDAQ:FTRE) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Thu, 22 Jan 2026
How Analyst Upgrades and Margin Progress Will Impact Fortrea Holdings (FTRE) Investors - Sahm
Thu, 22 Jan 2026
Beyond The Numbers: 7 Analysts Discuss Fortrea Holdings Stock - Benzinga
Tue, 20 Jan 2026
Fortrea Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fortrea Holdings, Inc. - FTRE - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 92 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 104.6 (%) |
| Shares Short | 10,180 (K) |
| Shares Short P.Month | 9,910 (K) |
| EPS | -11.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.3 |
| Profit Margin | -36.8 % |
| Operating Margin | -0.6 % |
| Return on Assets (ttm) | -1.4 % |
| Return on Equity (ttm) | -98.2 % |
| Qtrly Rev. Growth | 3.9 % |
| Gross Profit (p.s.) | 5.55 |
| Sales Per Share | 29.87 |
| EBITDA (p.s.) | 0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 2 (M) |
| Levered Free Cash Flow | 135 (M) |
| PE Ratio | -1.47 |
| PEG Ratio | 0 |
| Price to Book value | 2.64 |
| Price to Sales | 0.55 |
| Price to Cash Flow | 1025.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |